No connection

Search Results

MLSS vs TELA

MLSS
Milestone Scientific Inc.
BEARISH
Price
$0.31
Market Cap
$27.4M
Sector
Healthcare
AI Confidence
95%
TELA
TELA Bio, Inc.
BEARISH
Price
$0.63
Market Cap
$28.2M
Sector
Healthcare
AI Confidence
95%

Valuation

P/E Ratio
MLSS
--
TELA
--
Forward P/E
MLSS
-7.75
TELA
-1.12
P/B Ratio
MLSS
8.86
TELA
4.44
P/S Ratio
MLSS
3.05
TELA
0.35
EV/EBITDA
MLSS
-4.42
TELA
-1.07

Profitability

Gross Margin
MLSS
71.4%
TELA
68.17%
Operating Margin
MLSS
-52.46%
TELA
-31.86%
Profit Margin
MLSS
-63.77%
TELA
-48.37%
ROE
MLSS
-132.38%
TELA
-223.35%
ROA
MLSS
-40.45%
TELA
-25.12%

Growth

Revenue Growth
MLSS
2.2%
TELA
18.2%
Earnings Growth
MLSS
--
TELA
--

Financial Health

Debt/Equity
MLSS
0.36
TELA
9.13
Current Ratio
MLSS
1.81
TELA
4.21
Quick Ratio
MLSS
0.44
TELA
3.4

Dividends

Dividend Yield
MLSS
--
TELA
--
Payout Ratio
MLSS
0.0%
TELA
0.0%

AI Verdict

MLSS BEARISH

MLSS exhibits severe financial distress, highlighted by a Piotroski F-Score of 1/9, indicating critical weakness across nearly all fundamental health dimensions. The company suffers from chronic unprofitability with a profit margin of -63.77% and an ROE of -132.38%, while revenue growth has stagnated at a negligible 2.20% YoY. Despite a low debt-to-equity ratio, the poor quick ratio (0.44) and consistent earnings misses over 25 quarters suggest a failing business model. The stock is technically bearish with a 5-year price decline of 87.7%, making it a high-risk speculative asset with no fundamental floor.

Strengths
Strong gross margin of 71.40% suggesting a viable product core
Low Debt/Equity ratio (0.36) indicating minimal long-term leverage
Current ratio of 1.81 provides a temporary liquidity buffer
Risks
Critical financial health (Piotroski F-Score 1/9)
Chronic net losses with negative profit and operating margins
Stagnant revenue growth (2.20%) failing to scale the business
TELA BEARISH

TELA exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9 and a catastrophic ROE of -223.35%. While the company maintains a strong gross margin (68.17%) and modest revenue growth (18.2%), these are completely offset by extreme leverage (Debt/Equity of 9.13) and a consistent 25-quarter history of negative earnings. The stock's 5-year price collapse of 95.4% reflects a fundamental loss of investor confidence that is not countered by any meaningful insider buying or operational profitability.

Strengths
Strong Gross Margin of 68.17% indicating product value
Positive YoY Revenue Growth of 18.20%
High Current Ratio (4.21) providing short-term liquidity
Risks
Extreme financial leverage with a Debt/Equity ratio of 9.13
Severe lack of profitability with an ROE of -223.35%
Critical financial health as indicated by a Piotroski F-Score of 1/9

Compare Another Pair

MLSS vs TELA: Head-to-Head Comparison

This page compares Milestone Scientific Inc. (MLSS) and TELA Bio, Inc. (TELA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile